Skip to content

A Phase 1b study of inhaled RCT1100 in Adults with Primary Ciliary Dyskinesia Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-510521-14-00
Acronym
RCT1100-103
Enrollment
12
Registered
2024-05-28
Start date
2024-10-18
Completion date
2025-09-19
Last updated
2025-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adults with Primary Ciliary Dyskinesia

Interventions

None listed

Sponsors

Recode Therapeutics Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Countries

Denmark, Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026